Caladrius Biosciences Inc (CLBS.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2015||Chief Executive Officer, Independent Director|
|47||2015||Chief Financial Officer, Senior Vice President|
|58||2013||Chief Medical Officer|
- BRIEF-Caladrius Biosciences Announces Completion Of Enrollment Of Phase 2 T-Rex Clinical Trial Of CLBS03 For Type 1 Diabetes
- BRIEF-Caladrius Biosciences reports 2017 third quarter results
- BRIEF-Caladrius Biosciences files for resale of co's common stock by the selling stockholders
- BRIEF-Caladrius Biosciences Q2 loss per share $0.22 from continuing operations
- BRIEF-Caladrius Biosciences says 50 pct of subjects have been treated in the phase 2 clinical trial of CLBS03